The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Achieving over 11 g/L titers with intensified CHO cell culture optimization
Optimization of n-1 process intensification strategies that increase yield, reduce batch requirements, and maintain molecule viability.
Increased demand for higher product yield in biologics requires optimal use of existing manufacturing capacity. Process intensification is one way a facility can meet increased demand as it allows for fewer or smaller batches to provide the same amount of product in the same timeframe. Significant gains in cell growth and productivity have been achieved as previously presented by modification of media and feeds,1 capturing many of the benefits of perfusion without the additional costs related to equipment, facility upgrades, and training. However, clones may respond to intensification with varying results. Optimization beyond medium enrichment and feed amount may be required for clones with higher specific productivity.
This poster shows an optimization of an intensified fed-batch process, assessing initial feed amount, feed tapering during production, and temperature shift. The inclusion of a feed taper was designed to limit the nutrients during the stationary phase to optimize productivity.
Download the case study to see how our optimized intensified process, leveraging our CHO K1 cell lines, consistently increased titer levels without compromising molecule viability.
Key highlights include:
- An intensified fed-batch process, assessing initial feed amount, feed tapering during production, and temperature shift.
- Consistent increase in titer levels across two clones for Herceptin and Rituximab.
- Real-world success with titer levels of up to 11 g/L achieved.
Additional resources
CHO cell culture process intensification for enhanced production of IgG mAbs
Download the case study to see how our scientists leveraged existing manufacturing platforms and facilities with CHO K1 cell lines to increase titer levels by 80% without compromising quality.
Whitepaper
First-in-Human: Reach milestones sooner with a technology-driven approach to early-stage biologic development
This white paper explores our Path to IND program, which integrates next-generation technologies to accelerate biologics from discovery to clinic, including FiH trials.
Webinar
Accelerating biologics: From final DNA to Phase I in under 9 months
Originally presented at BIO International 2025, this webinar explores how Path to IND helps biotech companies move from DNA to first-in-human Phase I clinical trials in as little as nine months.*